• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Technology·EQS.PA
Share

Equasens Societe anonyme Stocks

€ 31.4Last Updated 07.09.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

€ 567.68M

€ 31.4
Key Takeaways

Risk factor

Limited trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their networks with advanced management systems, including LGPI global services and OffiCentral. Pharmacists leverage a comprehensive suite of tools designed to streamline daily business operations, such as OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker. To foster stronger customer relationships and engagement, Equasens provides innovative solutions like OffiTag, OffiTouch, OffiMédia, OffiConnect, alongside automation systems and loyalty program management. Beyond operational software, the company offers analytical insights through its My Pilot tool and professional development opportunities via OffiLearning, an e-learning platform. A key area of focus is patient support, with offerings spanning compliance monitoring software, Multimeds, Automeds, OffiTéléconsult, and essential pharmaceutical and shared medical record services. The company's specialized systems include ULTIMATE, which combines efficient pharmacy administration with enhanced patient care, and FARMACLICK, a protocol facilitating communication between pharmacies and wholesale distributors (the latter also served by DIFARM). Additional retail management tools comprise PHARE and the SOPHIA pharmacy application, complemented by OffiMédia POS displays. Equasens also addresses specific health needs, such as chronic renal failure management with eNephro, and simplifies the administration of patient education programs through TPE Pilot. Further extending its reach across the healthcare sector, Equasens offers various dedicated solutions like NOVIACARE, CARELIB (for home and nursing home care), KAPELSE, TITAN, ANTHADINE software, the MOBISOINS mobile tool, MICROSOINS for in-home nursing care, and LOGICLIC. For holistic patient journey oversight, the AXIGATE solutions and CHORUS platform are available. Supplementary services include medical telesecretarial assistance for healthcare professionals and equipment lease financing options. Equasens S.A. functions as a subsidiary of Marque Verte Sante.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of EQS.PA is 57.6 and suggests 83.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

09.09.2026 12:00

Computing Power Goes Public: Why Investors Should Consider GPU Rental Futures

09.09.2026 11:28

Revolut Plans to Poach Business Clients from Barclays and HSBC — FT

09.09.2026 10:33

Top Stories This Morning: Iran Claims to Have Struck U.S. Ships; Meta Launches AI Agent "Muse"

09.09.2026 09:00

The AI boom is running into an energy shortage. What indicators should investors watch for?

09.09.2026 08:00

Tesla, IBM, McDonald’s: Evercore Names Stocks Threatened by AI Giants’ IPOs

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026